BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance

BRISTOL MYERS SQUIBB CO

2025-Q2 EPS reported $1.85 revenue$23,470,000,000

Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).
GAAP EPS $0.64 vs $0.83 YoY; non-GAAP EPS $1.46 vs $2.07 YoY, both hit by $(0.57) BioNTech IPRD charge.
2025 revenue guidance raised to ~$46.5B–$47.5B; non-GAAP EPS guidance updated to $6.35–$6.65.
BioNTech strategic partnership resulted in a $0.57 per share Acquired IPRD charge in Q2.
CEO cites strong Growth Portfolio execution, cost optimization, and pipeline partnerships.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.